Ovarian Hyperstimulation Syndrome (OHSS)

Women's Health
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
Highly purified menotropinN/A1 trial
Active Trials
NCT01703728Completed455Est. May 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ferring PharmaceuticalsHighly purified menotropin

Clinical Trials (1)

Total enrollment: 455 patients across 1 trials

NCT01703728Ferring PharmaceuticalsHighly purified menotropin

Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.

Start: Nov 2012Est. completion: May 2014455 patients
N/ACompleted

Related Jobs in Women's Health

Senior Medical Science Liaison

Ferring Pharmaceuticals
Bangkok, Thailand
Yesterday

Senior Key Account Manager

Ferring Pharmaceuticals
Bucureşti, Romania
1w ago

Territory Representative - Miami

Caldera Medical
Miami, FL, US
1w ago

Senior Client Solutions Manager

Progyny
New York, New York
1w ago
$85K - $95K/yr

Sales Representative, Women's Health - Charleston, SC

Viatris (2)
Remote
1w ago
$72K - $108K/yr

Sales Representative Gynecological Health

Medtronic
Malaga, Andalucia, Spain
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Endometriosis(43)Menopause(27)Polycystic Ovary Syndrome(14)Postmenopause(8)Controlled Ovarian Stimulation(5)Vasomotor Symptoms Associated With Menopause(4)Polycystic Ovarian Syndrome(3)Preeclampsia(3)Uterine Fibroids(3)Uterine Leiomyomata (Fibroids)(3)